DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today that the first patient has been enrolled, on July 31, in the ...
HOUSTON — The daily application of a skin patch (Viaskin, DBV Technologies) that releases peanut protein is effective and safe for peanut immunotherapy, according to the largest clinical trial in ...
DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association Primary endpoint of Phase IIb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results